Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
机构：[1]Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China四川省肿瘤医院[2]Department ofMedical Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou,China[3]Department of Medical Oncology, Chongqing University Three Gorges Hospital,Chongqing, China[4]Department of Medical Oncology, Sichuan Cancer Hospitaland Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu,China四川省肿瘤医院[5]Department of Gastrointestinal Surgery, Chongqing University Cancer Hospital,Chongqing, China
第一作者机构：[1]Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China
推荐引用方式(GB/T 7714)：
Jin Y.,Han Y.,Zhang L.,et al.Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC[J].ANNALS OF ONCOLOGY.2022,33(7):S720-S721.doi:10.1016/j.annonc.2022.07.540.
APA：
Jin, Y.,Han, Y.,Zhang, L.,Jin, Y.&Sun, H..(2022).Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.ANNALS OF ONCOLOGY,33,(7)
MLA：
Jin, Y.,et al."Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC".ANNALS OF ONCOLOGY 33..7(2022):S720-S721
医学